Literature DB >> 16012724

FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.

Monica Spinola1, Vera Piera Leoni, Jun-Ichi Tanuma, Angela Pettinicchio, Milo Frattini, Stefano Signoroni, Roberto Agresti, Riccardo Giovanazzi, Silvana Pilotti, Lucio Bertario, Fernando Ravagnani, Tommaso A Dragani.   

Abstract

A functional Gly388Arg variation in the FGFR4 gene has been reported to be associated with breast and colorectal cancer prognostic parameters. To further examine the functional role of this genetic polymorphism at the population level, we assessed the presence of the Arg388 allele in 142 breast carcinoma patients, 179 colorectal carcinoma patients and 220 general population controls with respect to an association with cancer prognosis and/or risk. No significant association with cancer risk, survival or any other prognostic parameters was observed in either breast or colorectal cancer. A pooled analysis of the present and published data on nodal status by FGFR4 genotypes revealed no association in either breast cancer [odds ratio (OR), 1.0; 95% confidence interval (CI), 0.7-1.4; 702 subjects] or colorectal cancer (OR, 1.4; 95% CI, 0.6-3.4; 260 cases). Thus, the FGFR4 polymorphism may not be relevant in predicting nodal involvement of breast cancer or colon cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012724

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  27 in total

1.  HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women.

Authors:  Anna P Batschauer; Nathalia G Cruz; Vanessa C Oliveira; Fernanda F Coelho; Izabela R Santos; Michelle T Alves; Ana P Fernandes; Maria G Carvalho; Karina B Gomes
Journal:  Mol Cell Biochem       Date:  2011-05-28       Impact factor: 3.396

2.  Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.

Authors:  Yan-Ying Shen; Ya-Chao Lu; Dan-Ping Shen; Yuan-Jie Liu; Xin-Ying Su; Guan-Shan Zhu; Xiao-Lu Yin; Xing-Zhi Ni
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

3.  FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.

Authors:  Susana Garcia-Recio; Aatish Thennavan; Michael P East; Joel S Parker; Juan M Cejalvo; Joseph P Garay; Daniel P Hollern; Xiaping He; Kevin R Mott; Patricia Galván; Cheng Fan; Sara R Selitsky; Alisha R Coffey; David Marron; Fara Brasó-Maristany; Octavio Burgués; Joan Albanell; Federico Rojo; Ana Lluch; Eduardo Martinez de Dueñas; Jeffery M Rosen; Gary L Johnson; Lisa A Carey; Aleix Prat; Charles M Perou
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

4.  FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.

Authors:  Hong-mei Fang; Gang Tian; Li-juan Zhou; Han-ying Zhou; Ying-zhi Fang
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

5.  Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.

Authors:  L M FitzGerald; E Karlins; D M Karyadi; E M Kwon; J S Koopmeiners; J L Stanford; E A Ostrander
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-09-02       Impact factor: 5.554

6.  Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.

Authors:  Tarrik M Zaid; Tsz-Lun Yeung; Melissa S Thompson; Cecilia S Leung; Tom Harding; Ngai-Na Co; Rosie S Schmandt; Suet-Ying Kwan; Cristian Rodriguez-Aguay; Gabriel Lopez-Berestein; Anil K Sood; Kwong-Kwok Wong; Michael J Birrer; Samuel C Mok
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

Review 7.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 8.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  [Role of tyrosine kinases in tumor progression of the head and neck].

Authors:  C Bergmann; E Wimmer
Journal:  HNO       Date:  2009-02       Impact factor: 1.284

10.  Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.

Authors:  Christine Heinzle; Andrea Gsur; Monika Hunjadi; Zeynep Erdem; Christine Gauglhofer; Stefan Stättner; Josef Karner; Martin Klimpfinger; Friedrich Wrba; Andrea Reti; Balazs Hegedus; Andreas Baierl; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Cancer Res       Date:  2012-09-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.